Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Moshe Ornstein, MD.
EP. 1: Frontline Therapy Options for Advanced RCC and Combining IO and TKI in the First-line Setting in mRCC
A summary of frontline treatment options for metastatic renal cell carcinoma and the rationale for the combination of lenvatinib plus pembrolizumab.
EP. 2: Design and Key Takeaways of the CLEAR Study in Metastatic RCC
Results of the efficacy and safety data demonstrated by the CLEAR study of lenvatinib plus pembrolizumab or everolimus as first-line treatment for metastatic renal cell carcinoma.
EP. 3: Dosing Considerations for lenvatinib plus pembrolizumab in mRCC
Dr Moshe Ornstein examines dosing considerations for the combination of lenvatinib plus pembrolizumab in clinical practice and how that compares with the findings from the CLEAR study.
EP. 4: Implications of the CLEAR study in mRCC to Clinical Practice
Implications for treating patients with metastatic renal cell carcinoma with frontline lenvatinib plus pembrolizumab based on the regimen’s performance in the CLEAR study compared with other treatment options.
EP. 5: Subgroup Analyses of the CLEAR study in mRCC
An overview of data demonstrated by other investigational studies of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.
EP. 6: Future Direction for Patients With mRCC
Discussing future needs and investigating novel therapies for newly diagnosed metastatic renal cell carcinoma.
2 Clarke Drive Cranbury, NJ 08512